Boehringer Ingelheim's Ofev, or nintedanib, indicated as a treatment for systemic sclerosis-associated interstitial lung disease, received a positive opinion from the FDA's Arthritis Advisory Committee recommending the treatment for the agency's approval. If approved, Ofev will become the first treatment to be commercialized for US patients with SSc-ILD.
FDA committee recommends Boehringer's nintedanib for approval
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.